Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 200.22 Billion KRW | -4.33% |
| 2022 | 209.28 Billion KRW | 10.6% |
| 2021 | 189.23 Billion KRW | -4.31% |
| 2020 | 197.75 Billion KRW | 4.23% |
| 2019 | 189.72 Billion KRW | 1.24% |
| 2018 | 187.38 Billion KRW | 1.29% |
| 2017 | 184.99 Billion KRW | -4.71% |
| 2016 | 194.14 Billion KRW | -0.92% |
| 2015 | 195.95 Billion KRW | -11.05% |
| 2014 | 220.29 Billion KRW | 2.0% |
| 2013 | 215.96 Billion KRW | -2.35% |
| 2012 | 221.16 Billion KRW | -3.71% |
| 2011 | 229.69 Billion KRW | -1.02% |
| 2010 | 232.06 Billion KRW | 6.81% |
| 2009 | 217.25 Billion KRW | 15.48% |
| 2008 | 188.13 Billion KRW | 13.39% |
| 2007 | 165.92 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 56.02 Billion KRW | 3.74% |
| 2024 Q1 | 54 Billion KRW | 8.86% |
| 2023 Q1 | 48.36 Billion KRW | -17.73% |
| 2023 Q2 | 53.11 Billion KRW | 9.82% |
| 2023 Q4 | 49.6 Billion KRW | 0.97% |
| 2023 Q3 | 49.13 Billion KRW | -7.5% |
| 2023 FY | 200.22 Billion KRW | -4.33% |
| 2022 Q2 | 50.36 Billion KRW | 7.74% |
| 2022 Q4 | 58.79 Billion KRW | 10.15% |
| 2022 FY | 209.28 Billion KRW | 10.6% |
| 2022 Q3 | 53.37 Billion KRW | 5.97% |
| 2022 Q1 | 46.75 Billion KRW | -5.95% |
| 2021 Q1 | 44.97 Billion KRW | -8.83% |
| 2021 Q2 | 46.16 Billion KRW | 2.66% |
| 2021 Q3 | 48.38 Billion KRW | 4.81% |
| 2021 Q4 | 49.7 Billion KRW | 2.73% |
| 2021 FY | 189.23 Billion KRW | -4.31% |
| 2020 Q4 | 49.32 Billion KRW | 2.55% |
| 2020 Q1 | 49.13 Billion KRW | 1.42% |
| 2020 FY | 197.75 Billion KRW | 4.23% |
| 2020 Q3 | 48.1 Billion KRW | -6.01% |
| 2020 Q2 | 51.18 Billion KRW | 4.16% |
| 2019 Q3 | 48.03 Billion KRW | 3.23% |
| 2019 Q2 | 46.53 Billion KRW | -0.35% |
| 2019 Q1 | 46.7 Billion KRW | -7.42% |
| 2019 Q4 | 48.44 Billion KRW | 0.86% |
| 2019 FY | 189.72 Billion KRW | 1.24% |
| 2018 Q4 | 50.44 Billion KRW | 8.4% |
| 2018 FY | 187.38 Billion KRW | 1.29% |
| 2018 Q3 | 46.53 Billion KRW | -4.52% |
| 2018 Q2 | 48.73 Billion KRW | 16.93% |
| 2018 Q1 | 41.67 Billion KRW | -2.93% |
| 2017 Q2 | 49.72 Billion KRW | 6.62% |
| 2017 Q1 | 46.63 Billion KRW | 1.05% |
| 2017 FY | 184.99 Billion KRW | -4.71% |
| 2017 Q4 | 42.93 Billion KRW | -6.05% |
| 2017 Q3 | 45.69 Billion KRW | -8.1% |
| 2016 Q3 | 48.78 Billion KRW | -5.29% |
| 2016 Q4 | 46.15 Billion KRW | -5.39% |
| 2016 Q1 | 47.7 Billion KRW | -8.24% |
| 2016 FY | 194.14 Billion KRW | -0.92% |
| 2016 Q2 | 51.5 Billion KRW | 7.97% |
| 2015 FY | 195.95 Billion KRW | -11.05% |
| 2015 Q1 | 50.56 Billion KRW | -4.66% |
| 2015 Q4 | 51.98 Billion KRW | 11.72% |
| 2015 Q3 | 46.53 Billion KRW | -0.69% |
| 2015 Q2 | 46.86 Billion KRW | -7.31% |
| 2014 Q4 | 53.03 Billion KRW | -15.46% |
| 2014 Q1 | 51.21 Billion KRW | -2.41% |
| 2014 FY | 220.29 Billion KRW | 2.0% |
| 2014 Q2 | 53.31 Billion KRW | 4.11% |
| 2014 Q3 | 62.73 Billion KRW | 17.66% |
| 2013 Q2 | 55.76 Billion KRW | -0.77% |
| 2013 Q3 | 51.52 Billion KRW | -7.62% |
| 2013 Q4 | 52.47 Billion KRW | 1.85% |
| 2013 FY | 215.96 Billion KRW | -2.35% |
| 2013 Q1 | 56.2 Billion KRW | -0.16% |
| 2012 Q4 | 56.28 Billion KRW | -0.62% |
| 2012 FY | 221.16 Billion KRW | -3.71% |
| 2012 Q1 | 47.07 Billion KRW | 0.0% |
| 2012 Q2 | 59.26 Billion KRW | 25.91% |
| 2012 Q3 | 56.63 Billion KRW | -4.44% |
| 2011 Q2 | 56.67 Billion KRW | -1.05% |
| 2011 Q3 | 55.21 Billion KRW | -2.57% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 229.69 Billion KRW | -1.02% |
| 2011 Q1 | 57.27 Billion KRW | 0.0% |
| 2010 Q1 | 53.19 Billion KRW | 0.0% |
| 2010 FY | 232.06 Billion KRW | 6.81% |
| 2010 Q3 | 55.84 Billion KRW | -5.17% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 58.88 Billion KRW | 10.7% |
| 2009 Q1 | 47.75 Billion KRW | 0.0% |
| 2009 Q2 | 52.75 Billion KRW | 10.47% |
| 2009 Q3 | 51.22 Billion KRW | -2.9% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 217.25 Billion KRW | 15.48% |
| 2008 Q3 | 45.36 Billion KRW | -3.32% |
| 2008 Q1 | 42.38 Billion KRW | 0.0% |
| 2008 FY | 188.13 Billion KRW | 13.39% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 46.91 Billion KRW | 10.69% |
| 2007 Q3 | 38.55 Billion KRW | -8.31% |
| 2007 Q2 | 42.04 Billion KRW | 9.58% |
| 2007 Q1 | 38.37 Billion KRW | 0.0% |
| 2007 FY | 165.92 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -45.929% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 82.312% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 68.638% |
| HANDOK Inc. | 522.74 Billion KRW | 61.696% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -47.909% |
| Yuhan Corporation | 1858.98 Billion KRW | 89.229% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 69.844% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -285.388% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 86.57% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -48.417% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 45.963% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -126.008% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -18.082% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 10.794% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -45.929% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -156.528% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -32.539% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -129.19% |
| JW Holdings Corporation | 928.07 Billion KRW | 78.425% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 66.671% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 88.006% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.25% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -10.769% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -1.978% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 72.435% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -45.929% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 86.779% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 85.441% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.25% |
| Yuhan Corporation | 1858.98 Billion KRW | 89.229% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 74.805% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 14.761% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 66.324% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 73.25% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 31.459% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 28.219% |
| CKD Bio Corp. | 160.35 Billion KRW | -24.868% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 62.003% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 44.552% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 13.093% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 77.241% |
| Boryung Corporation | 859.62 Billion KRW | 76.707% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -59.002% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 45.963% |
| JW Lifescience Corporation | 206.86 Billion KRW | 3.206% |